veterans with type 2 diabetes, the WashU Medicine team found GLP-1s are tied to a reduced risk of developing substance use disorders across all major addictive substances and to a reduced risk of severe harm, including overdose and death, in people who already have such disorders
Understanding withdrawal patterns from GLP-1 agonists helps you plan your exit strategy proactively
However, the drugs manufacturer, Novo Nordisk, does not report it as a side effect
Chemical modification, new networks of polymers, and overall insertion of micron-sized particles, such as carbon-based, polymeric, and inorganic nanoparticles, can all be categorized as modification techniques (Feng and Wang, 2022)